Efficacy and Safety of Romosozumab as a Medication for Osteoporosis in Postmenopausal Women: A Literature Review
Bibliographic record
Abstract
Introduction: Osteoporosis is a systemic skeletal condition in which bone mineral density is markedly decreased. Romosozumab, a monoclonal antibody, has been approved for osteoporosis use in Canada since 2019. Further assessment of which patient population(s) and when to use romosozumab for greatest effect is needed. Methods: A literature search was conducted on the PubMed database, looking at any randomized controlled trial and clinical trial with the keyword “romosozumab” published between 2015 and 2025. Results: Four studies met the criteria for inclusion. All studies demonstrated significant improvements in bone mineral density (BMD) at the lumbar spine, femoral neck, and hip. Greatest BMD gains were observed at the lumbar spine uniformly throughout the studies. Most commonly observed adverse effects in romosozumab patients include mild injection site reactions and arthralgia. Incidence of serious events related to romosozumab use was noted in one study. Conclusion: Romosozumab was seen to significantly improve BMD and have a favorable safety profile in most patients, however limited insight into which patient population would benefit most from treatment. Currently, not enough evidence in literature to suggest romosozumab as first line treatment.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.007 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.003 | 0.002 |
| Bibliometrics | 0.008 | 0.008 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.004 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".